|
|
|
|
NB1011
A substance that is being studied for its ability to make cancer cells respond to drugs to which they have become resistant. It belongs to the family of drugs called nucleoside analogs. (National Cancer Institute)
Archives: The following articles may no longer be available on the web. If you want to inquire on a particular article, please contact the source publication (listed in parentheses).
Celmed BioSciences to acquire NewBiotics of San Diego Jun 7, 2004
The most advanced product is NB1011, a compound in Phase l/ll clinical trials that exploits thymidylate synthase (TS), an enzyme widely studied and reported in ... Yahoo News (press release) -
Theratechnologies Restructures Ahead Of Phase III ThGRF Trial Jun 8, 2004
...oncology. NewBiotics' most advanced product is NB1011, a compound in Phase I/II trials that exploits the enzyme thymidylate synthase. ... BioWorld Online (subscription) -
Resources from the National Cancer Institute on NB1011:
[an error occurred while processing this directive]
|
|
|
